Abstract: The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system.

Abstract: Methods and compositions for modulating brain pathways and functions are disclosed.

Abstract: The invention relates to systems and methods for analyzing clinically relevant nucleic acid sequences.

Abstract: A radioassay test for the rapid and sensitive determination of the concentration of monosialoglycosphingolipid G.sub.M1 ganglioside concentrations in small volumes of cerebrospinal fluid from individual patients is based on the high affinity interaction between cholera enterotoxin and G.sub.M1 ganglioside. The level of G.sub.M1 ganglioside present in the cerebrospinal fluid has been shown to be an indicator of active central nervous system pathology. In the present invention, the use of highly specific toxins eliminates cross reactivity with the other gangliosides, thereby eliminating the need to process the cerebrospinal sample prior to assay, except for centrifugation. Results of a specific application of the subject radioassay to newborn infants and older infants and children (some of the latter having active neurologic disease) indicated that the G.sub.M1 ganglioside concentration in the cerebrospinal fluid is probably a function of both central nervous system tissue ganglioside content and turnover.